Study Type
Interventional - Drug
completed
The WAVE trial was a phase III international, multi-center RCT of warfarin plus antiplatelet therapy versus antiplatelet therapy alone in patients with peripheral arterial disease (PAD).
This was one of the largest trials to-date conducted in patients with PAD.
Co-primary endpoints:
- Composite of CV death, MI, or stroke
- Severe ischemia requiring reperfusion/reconstruction of the coronary or peripheral arterial circulation.
Secondary endpoints:
- CV death, MI, stroke, amputation, revascularization of the coronary or peripheral arterial circulation
- CV death, MI, stroke, amputation, revascularization and severe coronary ischemia with ECG changes
- Death, MI, TIA, stroke, amputation, coronary or peripheral revascularization and severe coronary ischemia with ECG changes.
All primary and secondary endpoints were adjudicated.
Study Design
Randomized, open label, parallel group design.
NO. of Countries
7
NO. of Sites
80
NO. of Participants
2161
Study Period
2000-2006
Sponsor
PHRI
Sonia Anand
Senior Scientist
Sonia Anand
Senior Scientist
Sonia Anand is a Professor, Medicine and Epidemiology at McMaster University; Associate Chair, Diversity and Equity in McMaster’s Department of Medicine; Director of McMaster’s Population Genomics Program; inaugural Chair, Equity, Diversity and Inclusion (EDI) Committee of the Canadian Cardiovascular Society; and Director, Chanchlani Research Centre for Global Health at McMaster, among other roles.
Her present research focuses upon the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease. Sonia has published more than 200 articles in peer review journals. Shas been inducted into the Canadian Academy of Health Sciences, and received the Queen Elizabeth II Diamond Jubilee Medal.
